| Name | Title | Contact Details |
|---|---|---|
Tom Langan |
President and Chief Commercial Officer | Profile |
Lisa Khorey |
Executive Vice President, Chief Client Delivery Officer | Profile |
John Sage |
Senior Vice President, Client Org | Profile |
Russell Cook |
Vice President Of Product Development | Profile |
Julian Mitchell |
Vice President of Product Development | Profile |
Verisys is the leading provider of the most comprehensive data, coupled with deep healthcare industry experience to screen, monitor, verify and credential the individuals and entities you care about. Keeping bad actors out of the healthcare system makes it safer for everyone. Featuring FACIS, CheckMedic, ProviderCheck, and more.
Neovia benefits from a multi-activities, multi-species and multi-areas experience. It is a reference in terms of innovative solutions in breeding.
VITAS Innovative Hospice Care, a pioneer and leader in the hospice movement since 1978, is the one of the nations largest providers of end-of-life care.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
P.volve is a rapidly growing start-up and omnichannel health & wellness brand with an on-demand movement platform, a patented equipment line, three studio locations, franchise opportunities worldwide and a recovery supplement. Our team is comprised of highly passionate, hardworking professionals who live and breathe our Method and business. When a team member starts at P.volve, they will feel the infectious positivity and dedication to our mission.